AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02929329
Drug: Omecamtiv Mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil tablets for oral administration
Trial: NCT00864201
Drug: bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
Trial: NCT00628576
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
Trial: NCT00628576
Drug: Tinzaparin (Leo)
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
Trial: NCT01985165
Drug: Imrecoxib
RxNorm normalized name: Imrecoxib
DrugBank: Imrecoxib (DB12354)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02802072
Drug: Only aspirin medication
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
Trial: NCT00621101
Drug: 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
RxNorm normalized name: (R)-LACOSAMIDE 1
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Trial: NCT02686853
Drug: Liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01898403
Drug: Indocyanine green solution
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered peri-tumoral and intradermally
Trial: NCT01898403
Drug: Isosulfan blue (ISB)
RxNorm normalized name: Isosulfan Blue
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered peri-tumoral and intradermally
Trial: NCT01637493
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
Trial: NCT03351361
Drug: Nivolumab + Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
Trial: NCT00657020
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge containing 4 mg of nicotine
Trial: NCT00179283
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00179283
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00703937
Drug: Ferric Carboxymaltose (FCM)
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01475279
Drug: Warfarin; Dantonic
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
Trial: NCT00519519
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous 80mg bolus followed by 8mg / hr for 3 days
Trial: NCT02389582
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use for 5 days
Trial: NCT02389582
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use for 5 days
Trial: NCT01066520
Drug: Traumeel S ointment
RxNorm normalized name: S-2
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g, 3 times daily topical during 14 days
Trial: NCT01365520
Drug: turoctocog alfa
RxNorm normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
Trial: NCT01154036
Drug: ezetimibe 10 mg
RxNorm normalized name: ezetimibe 10 MG
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01066520
Drug: Traumeel S gel
RxNorm normalized name: S-2
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g, 3 times daily topical during 14 days
Trial: NCT01238796
Drug: telavancin
RxNorm normalized name: Telavancin
DrugBank: Telavancin (DB06402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00926965
Drug: amisulpride
RxNorm normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amisulpride tablet 100-1200mg/day for 24 months
Trial: NCT00926965
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine tablet 2.5 to 30 mg/day for 24 months
Trial: NCT01587729
Drug: Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
Trial: NCT02947087
Drug: Prolastin-C
RxNorm normalized name: Prolastin-C
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
Trial: NCT01075828
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
Trial: NCT01736800
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
Trial: NCT01736800
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
Trial: NCT00171808
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03255694
Drug: PEG-somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
Trial: NCT05141240
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants who initiated CDK4/6i therapy
Trial: NCT05141240
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants who initiated CDK4/6i therapy
Trial: NCT00543114
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
Trial: NCT00543114
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
Trial: NCT00543114
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on Day 1 of each 28 day cycle
Trial: NCT01327495
Drug: Acyline
RxNorm normalized name: Acyline
DrugBank: Acyline (DB11906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ug/kg subcutaneous injection every 2 weeks
Trial: NCT01786759
Drug: ClinOleic
RxNorm normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Trial: NCT01786759
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Trial: NCT02718430
Drug: VXM01
RxNorm normalized name: VXM01
DrugBank: VXM01 (DB17420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy targeting VEGFR2
Trial: NCT00307684
Drug: double blind PR OROS methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18, 36, 54,72 or 90 mg/day once daily for 4 weeks
Trial: NCT00307684
Drug: open label PR OROS methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
Trial: NCT03795805
Drug: Intaarticular lidocain
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
Trial: NCT02472314
Drug: 1.3% Liposomal Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local tissue infiltration of Liposomal Bupivacaine during surgery
Trial: NCT01235273
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: growth hormone administration
Trial: NCT00912262
Drug: Capsaicin Topical Liquid
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02478268
Drug: Hyperpolarized 129-Xenon gas
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
Trial: NCT02206152
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
Trial: NCT00004286
Drug: immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067520
Drug: intrathecal hydromorphone (IT hydromorphone)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01393145
Drug: Combination Fluticasone /Formoterol 12/250 μg
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
Trial: NCT00973245
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg od
Trial: NCT00005108
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00720772
Drug: 25% intravenous (IV) sodium thiosulfate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 ml IV drip twice/week post hemodialysis
Trial: NCT03386825
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antineoplastic agents, protein kinase inhibitor (L01XE21)
Trial: NCT00006011
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00006011
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02156726
Drug: low-dose FCR
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FCR with attenuated dose of fludarabine and cyclophosphamide
Trial: NCT02316327
Drug: gemcitabine, cisplatin and bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Therapeutic
Trial: NCT01888900
Drug: DUAL
RxNorm normalized name: Opdualag
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Asunaprevir and Daclatsvir
Trial: NCT01888900
Drug: QUAD
RxNorm normalized name: ProQuad
DrugBank: mu4-sulfido-quadro-tetracopper (DB03151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunaprevir, daclatsvir, peginterferon and ribavirin
Trial: NCT01639560
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
Trial: NCT00973245
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg od
Trial: NCT00973245
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20mg od
Trial: NCT01001338
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol
Trial: NCT01160289
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 12 weeks
Trial: NCT02357225
Drug: Pyridostigmine Bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
Trial: NCT01090180
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
Trial: NCT01467882
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder and solution for solution for injection
Trial: NCT02378389
Drug: Pyrotinib/Pyrotinib with Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
Trial: NCT00430846
Drug: SGN-35
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
Trial: NCT02875886
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined with amiloride
Trial: NCT01015547
Drug: Infliximab plus methotrexate
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Trial: NCT01015547
Drug: Combination of DMARDs
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Trial: NCT04470973
Drug: Cefuroxime
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive cefuroxime as part of standard care.
Trial: NCT00152932
Drug: Dorzolamide 2% drops
DrugBank: Dorzolamide (DB00869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04480138
Drug: Pegylated Interferon-α2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mcg/kg on day 1 and day 8 after safety evaluations.
Trial: NCT00219102
Drug: aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02774239
Drug: Human normal immunoglobulin G (IgG)
RxNorm normalized name: Human immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner.
Trial: NCT00034060
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05596071
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
Trial: NCT00570401
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00973245
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin based on target INR values
Trial: NCT00525382
Drug: levocetirizine dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02644291
Drug: Mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
Trial: NCT04143958
Drug: agalsidase beta (GZ419828)
RxNorm normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
Trial: NCT04143958
Drug: agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
Trial: NCT00501839
Drug: clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01452373
Drug: DHEA and Acolbifene
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Acolbifene (DB16080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
Trial: NCT01896323
Drug: CC-223
RxNorm normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-223 20 mg tablets
Trial: NCT01896323
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg tablets
Trial: NCT02786550
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
Trial: NCT02686684
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01075802
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation